# A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis

> **NCT00931762** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera
- Post-Essential Thrombocytopenia

## Interventions

- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT00931762
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08-31
- **Primary completion:** 2011-08-29
- **Final completion:** 2011-08-29
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931762, "A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00931762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*